Clinical trial
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic…
NCT00084721 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00084721 |
|---|---|
| Title | Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer |
| Official title | A Phase I Study of Irinotecan in Combination With Fixed Dose Celecoxib in Patients With Advanced Colorectal Cancer |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Diarrhea |
| Intervention type | Drug |
| Interventions | celecoxib, irinotecan hydrochloride |
| Enrollment | 2 |
| Start date | Mar 1, 2005 |
| Primary completion | Oct 1, 2005 |
| First posted | Jun 11, 2004 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: